Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study

Sexually Transmitted Diseases

Volumn 35, Issue 2, 2008, Pages 124-128

  Kim, H Nina ^a,d   Wald, Anna ^a,b,d   Harris, Julia ^c   Almekinder, Jennifer ^c   Heitman, Cathy ^c   Corey, Lawrence ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Powdermed ^*

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALACICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; DATA ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; FEMALE; GENITAL HERPES; HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOGAMY; MORBIDITY; RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SEXUALITY; VIRUS TRANSMISSION;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE TRANSMISSION, HORIZONTAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL PARTNERS; TREATMENT OUTCOME; VALINE; VIRUS SHEDDING;

EID: 38549148307     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31815407d7     Document Type: Article

References (20)

1. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795-1798.
2. Sanchez J, Volquez C, Totten PA, et al. The etiology and management of genital ulcers in the Dominican Republic and Peru. Sex Transm Dis 2002; 29:559-567.
3. Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: Predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243-246.
4. Bruisten SM, Cairo I, Fennema H, et al. Diagnosing genital ulcer disease in a clinic for sexually transmitted diseases in Amsterdam, The Netherlands. J Clin Microbiol 2001; 39:601-605.
5. Ahmed HJ, Mbwana J, Gunnarsson E, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two Tanzanian cities. Sex Transm Dis 2003; 30:114-119.
6. Gottlieb SL, Douglas JM Jr, Schmid DS, et al. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J Infect Dis 2002; 186:1381-1389.
7. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973.
8. Carney O, Ross E, Bunker C, et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994; 70:40-45.
9. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
10. Wald A, Langenberg AGM, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-3106.
11. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707-713.
12. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-667.
13. Jerome KR, Huang M-L, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40:2609-2611.
14. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
15. Wald A, Zeh J, Selke S, et al. Genital shedding of herpes simplex virus among men. J Infect Dis 2002; 186(suppl 1):S34-S39.
16. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331-340.
17. Blower S, Wald A, Gershengorn H, et al. Targeting virological core groups: A new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis 2004; 190:1610-1617.
18. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
19. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
20. Williams JR, Jordan JC, Davis EA, et al. Suppressive valacyclovir therapy: Impact on the population spread of HSV-2 infection. Sex Transm Dis 2007; 34:123-131.